Memantină Terapia (Memantine Hydrochloride)

Memantine is an NMDA receptor antagonist used in the management of neurodegenerative conditions, particularly Alzheimer’s disease.

• Mild Alzheimer’s disease: modest improvement in cognition and daily living activities.
• Moderate Alzheimer’s disease: stabilization of functional decline and behavioral symptoms.
• Severe Alzheimer’s disease: may provide modest benefit in global clinical status.
• Very mild Alzheimer’s disease: may delay onset of functional decline.

• Memantine acts as a non‑competitive antagonist at the N‑methyl‑D‑aspartate (NMDA) receptor ion channel. By binding within the receptor-associated channel at moderate affinity, it reduces excessive calcium influx caused by prolonged glutamate activation. This moderation of excitatory neurotransmission limits excitotoxic neuronal injury, which is implicated in the pathophysiology of Alzheimer’s disease, thereby supporting neuronal survival and function.

Memantine may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects

• Dizziness: transient sensation of light‑headedness.
• Headache: mild to moderate intensity.
• Constipation: reduced bowel movements.
• Fatigue: feeling of tiredness.
• Nausea: upset stomach.

Serious or Rare Side Effects

• Seizures: convulsive episodes, especially in predisposed patients.
• Severe allergic reactions: rash, angioedema, or anaphylaxis.
• Hallucinations or psychosis: visual or auditory disturbances.
• Cardiac arrhythmias: irregular heart rhythm, rarely reported.

When prescribing Memantína Terapia, clinicians should consider several safety considerations.

• Renal impairment: dose may need adjustment in severe renal dysfunction.
• Hepatic impairment: monitor liver function tests during therapy.
• History of seizures: use with caution as the drug can lower seizure threshold.
• Concomitant use with other NMDA antagonists: avoid combined therapy due to additive effects.
• Pregnancy and lactation: safety not established; use only if potential benefit justifies risk.
• Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Memantine can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

• Amantadine: combined NMDA antagonism may increase neuropsychiatric adverse events.
• High‑dose quinidine: may raise memantine plasma concentrations.

Moderate Interactions (Monitor Closely)

• Anticholinergic agents: may reduce cognitive benefits of memantine.
• Carbamazepine: enzyme induction can lower memantine levels.
• Proton pump inhibitors (e.g., omeprazole): may increase memantine exposure.
• Alcohol: excessive use may exacerbate dizziness and CNS effects.
• CNS depressants (e.g., benzodiazepines): may enhance sedation.